Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Foresite Capital Opportunity Management V, LLC (CIK 1792207) reported $33.3M across 9 reported positions in its SEC 13F filing for 2022-09-30. Largest positions: PRDS ($9.7M, 29.04%), THRX ($5.6M, 16.71%), IRON ($4.0M, 11.99%), CMPX ($3.5M, 10.64%), KNTE ($3.5M, 10.46%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PRDS | Pardes Biosciences Inc | $9.7M | 29.04% | 5.2M | Hold |
| 2 | THRX | Theseus Pharmaceuticals, Inc. | $5.6M | 16.71% | 959,275 | Hold |
| 3 | IRON | Gemini Therapeutics, Inc. | $4.0M | 11.99% | 2.4M | Hold |
| 4 | CMPX | Compass Therapeutics, Inc. | $3.5M | 10.64% | 1.6M | Hold |
| 5 | KNTE | Kinnate Biopharma Inc. | $3.5M | 10.46% | 291,667 | Hold |
| 6 | ACET | Adicet Bio, Inc. | $2.4M | 7.26% | 170,000 | Hold |
| 7 | QSI | Quantum-Si Incorporated | $1.7M | 5.23% | 633,626 | Hold |
| 8 | HIMS | Hims & Hers Health, Inc. | $1.7M | 5.13% | 306,431 | Hold |
| 9 | ENTA | Enanta Pharmaceuticals, Inc. | $1.2M | 3.54% | 22,750 | Hold |
Source: SEC Form 13F filings · as of 2022-09-30